Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Patients' Access to Treatments Act of 2013
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
Patients' Access to Treatments Act of 2013
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2014 · first_quarter · Q1
Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
Source: Senate LDA
Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013.Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
Patients' Access to Treatments Act of 2013
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
Patients' Access to Treatments Act of 2013
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013.Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
Patients' Access to Treatments Act of 2013
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Access to care for people with psoriasis and psoriatic arthritis: H.R.460: Patients' Access to Treatments Act of 2012.Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012
Patients' Access to Treatments Act of 2012
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012
Patients' Access to Treatments Act of 2012
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012
Patients' Access to Treatments Act of 2012
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SECTION 4. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION Authorizes the Centers for Disease Control and Prevention (CDC) to undertake psoriasis and psoriatic arthritis data collection efforts including: incorporating questions into existing public health surveys, questionnaires and other databases to collect information regarding prevalence in the United States, age of onset, health-related quality of life, health care utilization, burden of disease (employment, work, etc.), direct and indirect costs, health disparities (age, gender, racial, ethnic), comorbidities and natural history of disease. These efforts may include the consideration and development of a patient registry, which would include individuals of all ages. SECTION 5. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS Non-binding language that: Recognizes that the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases. Commends the non-profit and private sector psoriasis research communities for planning a multi-disciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions. Encourages the National Institutes of Health (NIH) to continue to work with the organizations and private sector stakeholders who convene the multi-disciplinary scientific meeting to discuss future directions of psoriasis and comorbid research. Suggests that the non-profit and private sector meeting conveners disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from NIH and other relevant federal agencies. Encourages the Secretary of the Department of Health and Human Services (HHS), acting through the Director of the NIH, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) and other NIH institutes and centers, to utilize the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research and to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SECTION 4. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION Authorizes the Centers for Disease Control and Prevention (CDC) to undertake psoriasis and psoriatic arthritis data collection efforts including: incorporating questions into existing public health surveys, questionnaires and other databases to collect information regarding prevalence in the United States, age of onset, health-related quality of life, health care utilization, burden of disease (employment, work, etc.), direct and indirect costs, health disparities (age, gender, racial, ethnic), comorbidities and natural history of disease. These efforts may include the consideration and development of a patient registry, which would include individuals of all ages. SECTION 5. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS Non-binding language that: Recognizes that the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases. Commends the non-profit and private sector psoriasis research communities for planning a multi-disciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions. Encourages the National Institutes of Health (NIH) to continue to work with the organizations and private sector stakeholders who convene the multi-disciplinary scientific meeting to discuss future directions of psoriasis and comorbid research. Suggests that the non-profit and private sector meeting conveners disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from NIH and other relevant federal agencies. Encourages the Secretary of the Department of Health and Human Services (HHS), acting through the Director of the NIH, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) and other NIH institutes and centers, to utilize the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research and to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011
Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011
Client: NATIONAL PSORIASIS FOUNDATION · Firm: NATIONAL PSORIASIS FOUNDATION
Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011
Allocate $1.2 million in the Fiscal Year (FY) 2014 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at the Centers for Disease Control and Prevention (CDC).Allocate $1.2 million in the Fiscal Year (FY) 2014 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at the Centers for Disease Control and Prevention (CDC). With this funding, the CDCs National Center for Health Statistics (NCHS) could begin implementation of the first ever psoriasis and psoriatic arthritis public health agenda by developing survey instruments, which will: Increase the understanding of psoriasis, including the prevalence of the diseases and how age, sex, race, and ethnicity affect the course and burden of psoriasis; Study how differences in genetic and non-genetic factors, such as environmental exposure and life-style, contribute to the occurrence and severity of psoriasis and psoriatic arthritis; Examine the relationship of psoriasis to other serious diseases and develop public health strategies to reduce the burden of diseases and prevent the onset of comorbid conditions; and Gain insight into the long-term impact of psoriasis and psoriatic arthritis.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2013 · fourth_quarter · Q4
Allocate $1.2 million in the Fiscal Year (FY) 2014 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at the Centers for Disease Control and Prevention (CDC).Allocate $1.2 million in the Fiscal Year (FY) 2014 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at the Centers for Disease Control and Prevention (CDC). With this funding, the CDCs National Center for Health Statistics (NCHS) could begin implementation of the first ever psoriasis and psoriatic arthritis public health agenda by developing survey instruments, which will: Increase the understanding of psoriasis, including the prevalence of the diseases and how age, sex, race, and ethnicity affect the course and burden of psoriasis; Study how differences in genetic and non-genetic factors, such as environmental exposure and life-style, contribute to the occurrence and severity of psoriasis and psoriatic arthritis; Examine the relationship of psoriasis to other serious diseases and develop public health strategies to reduce the burden of diseases and prevent the onset of comorbid conditions; and Gain insight into the long-term impact of psoriasis and psoriatic arthritis.
Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2013 · third_quarter · Q3
Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013.Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
Allocate $1.2 million in the Fiscal Year (FY) 2014 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at the Centers for Disease Control and Prevention (CDC).Allocate $1.2 million in the Fiscal Year (FY) 2014 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at the Centers for Disease Control and Prevention (CDC). With this funding, the CDCs National Center for Health Statistics (NCHS) could begin implementation of the first ever psoriasis and psoriatic arthritis public health agenda by developing survey instruments, which will: Increase the understanding of psoriasis, including the prevalence of the diseases and how age, sex, race, and ethnicity affect the course and burden of psoriasis; Study how differences in genetic and non-genetic factors, such as environmental exposure and life-style, contribute to the occurrence and severity of psoriasis and psoriatic arthritis; Examine the relationship of psoriasis to other serious diseases and develop public health strategies to reduce the burden of diseases and prevent the onset of comorbid conditions; and Gain insight into the long-term impact of psoriasis and psoriatic arthritis.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2013 · second_quarter · Q2
Allocate $1.2 million in the Fiscal Year (FY) 2014 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at the Centers for Disease Control and Prevention (CDC).Allocate $1.2 million in the Fiscal Year (FY) 2014 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at the Centers for Disease Control and Prevention (CDC). With this funding, the CDCs National Center for Health Statistics (NCHS) could begin implementation of the first ever psoriasis and psoriatic arthritis public health agenda by developing survey instruments, which will: Increase the understanding of psoriasis, including the prevalence of the diseases and how age, sex, race, and ethnicity affect the course and burden of psoriasis; Study how differences in genetic and non-genetic factors, such as environmental exposure and life-style, contribute to the occurrence and severity of psoriasis and psoriatic arthritis; Examine the relationship of psoriasis to other serious diseases and develop public health strategies to reduce the burden of diseases and prevent the onset of comorbid conditions; and Gain insight into the long-term impact of psoriasis and psoriatic arthritis.
Access to care for people with psoriasis and psoriatic arthritis. -H.R.460: Patients' Access to Treatments Act of 2013.Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2013 · first_quarter · Q1
Allocate $1.2 million in the Fiscal Year (FY) 2014 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at the Centers for Disease Control and Prevention (CDC).Allocate $1.2 million in the Fiscal Year (FY) 2014 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at the Centers for Disease Control and Prevention (CDC). With this funding, the CDCs National Center for Health Statistics (NCHS) could begin implementation of the first ever psoriasis and psoriatic arthritis public health agenda by developing survey instruments, which will: Increase the understanding of psoriasis, including the prevalence of the diseases and how age, sex, race, and ethnicity affect the course and burden of psoriasis; Study how differences in genetic and non-genetic factors, such as environmental exposure and life-style, contribute to the occurrence and severity of psoriasis and psoriatic arthritis; Examine the relationship of psoriasis to other serious diseases and develop public health strategies to reduce the burden of diseases and prevent the onset of comorbid conditions; and Gain insight into the long-term impact of psoriasis and psoriatic arthritis.
Access to care for people with psoriasis and psoriatic arthritis: H.R.460: Patients' Access to Treatments Act of 2012.Support efforts to reduce impediments to treatment for individuals with moderate to severe psoriasis. The National Psoriasis Foudation supports the Patients' Access to Treatments Act of 2013 (introduced in the House as H.R. 460), which limits copayments, coinsurance, and other cost-sharing and out-of-pocket expenses for so-called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2012 · fourth_quarter · Q4
Support for the continuation of psoriasis and psoriatic arthritis data collection efforts at the Centers for Disease Control and Prevention (CDC). Allocate $1.2 million in the Fiscal Year 2013 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at CDC. With this funding, the CDCs National Center for Chronic Disease Prevention and Health Promotion could begin implementation of its public health agenda that, if implemented, will: 1. Increase the understanding of psoriasis, including the prevalence of the diseases and how age, sex, race and ethnicity affect the course and burden of psoriasis; 2. Study how differences in genetic and non-genetic factors, such as environmental exposure and life-style, contribute to the occurrence and severity of psoriasis and psoriatic arthritis; 3. Examine the relationship of psoriasis to other serious diseases and develop public health strategies to reduce the burden of diseases and prevent the onset of comorbid conditions; and 4. Gain insight into the long-term impact of psoriasis and psoriatic arthritis.
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2012 · third_quarter · Q3
Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012
H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2012 · second_quarter · Q2
Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012
H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2012 · first_quarter · Q1
Support for the continuation of psoriasis and psoriatic arthritis data collection efforts at the Centers for Disease Control and Prevention (CDC). Allocate $1.2 million in the Fiscal Year 2013 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at CDC. With this funding, the CDCs National Center for Chronic Disease Prevention and Health Promotion could begin implementation of its public health agenda that, if implemented, will: 1. Increase the understanding of psoriasis, including the prevalence of the diseases and how age, sex, race and ethnicity affect the course and burden of psoriasis; 2. Study how differences in genetic and non-genetic factors, such as environmental exposure and life-style, contribute to the occurrence and severity of psoriasis and psoriatic arthritis; 3. Examine the relationship of psoriasis to other serious diseases and develop public health strategies to reduce the burden of diseases and prevent the onset of comorbid conditions; and 4. Gain insight into the long-term impact of psoriasis and psoriatic arthritis.
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2011 · fourth_quarter · Q4
H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.
NATIONAL PSORIASIS FOUNDATION via NATIONAL PSORIASIS FOUNDATION
2011 · third_quarter · Q3
Support for the continuation of psoriasis and psoriatic arthritis data collection efforts at the Centers for Disease Control and Prevention (CDC). Submission of report language (see details on attached two pages) Project Name: Psoriasis and Psoriatic Arthritis Data Collection Amount Requested:$1,500,000 Legislative Report Language: Approximately 7.5 million Americans are affected by psoriasis and/or psoriatic arthritis chronic, inflammatory, painful and disfiguring autoimmune diseases for which there are limited treatment options and no cure. Psoriasis is the nations most prevalent autoimmune condition. Of additional concern is the mounting and compelling evidence of co-morbidities associated with psoriasis, including heart attack, diabetes, Crohns disease, cancer, obesity, and cardiovascular disease. Studies have established that the risk of premature death is 50 percent higher for people with severe psoriasis and that these individuals die four years younger, on average, than those without psoriasis. The Committee recognized the need for epidemiological and longitudinal data on individuals with psoriasis and psoriatic arthritis, including children and adolescents by providing appropriations beginning in FY 2010 to the Centers for Disease Control and Prevention (CDC) to support psoriasis and psoriatic arthritis data collection. The Committee is pleased with progress made by the CDC and notes that the federal investment thus far has established an important blueprint to better understand psoriasis, examine the relationship of psoriasis to other serious diseases, develop public health strategies to reduce the burden of diseases and prevent the onset of co-morbid conditions, and gain insight into the long-term impact of psoriasis and psoriatic arthritis. The Committee continues to support these efforts by providing $1.5 million in FY 2012 for psoriasis data collection. The Committee encourages the National Center for Chronic Disease Prevention and Health Promotion to continue to work with national organizations and stakeholders to refine and implement the psoriasis and psoriatic arthritis data collection process that has been established through the previous funding. Appropriations Bill: Labor, Health and Human Services, and Education Federal Agency: Department of Health and Human Services -- Centers for Disease Control and Prevention Account/Program: Health Promotion Description of Project CDC: This funding would be used by the CDCs National Center for Chronic Disease Prevention and Health Promotion to collect much-needed population-based data from patients suffering from psoriasis and psoriatic arthritis. This data would provide a better understanding of the prevalence of co-morbidities; how age, sex, race and ethnicity affect the course and burden of psoriasis; and how differences in genetic and non-genetic factors, such as environmental exposure and life-style, contribute to the occurrence and severity of psoriasis and psoriatic arthritis. Report language request supporting $1.5 million in FY 2012 for continuation of population-based data collection to further the understanding of psoriasis and psoriatic arthritis, autoimmune diseases that affect 7.5 million Americans. Data collected will contribute to improved disease treatment and management, and further the nation's efforts to find a cure. Project Name: NIH Office of the Director Amount Requested:N/A Legislative Report Language: The Committee is concerned that psoriasis, the nations most prevalent autoimmune condition, has an adverse impact on too many of the 7.5 million Americans who live with this disease and urges interagency efforts focused on collaborative interdisciplinary research to identify improved methods of treatment and control. The Committee recognizes the seriousness of psoriasis, in that it is a painful and physically, as well as psychologically, devastating disease. Of additional concern is the mounting and compelling evidence of co-morbidities associated with psoriasis, including heart attack, diabetes, Crohns disease, cancer, obesity, and cardiovascular disease. Studies have established that the risk of premature death is 50 percent higher for people with severe psoriasis and that these individuals die four years younger, on average, than those without psoriasis. The Committee urges NIH to advance integrated interdisciplinary biomedical research focused on the systemic inflammatory nature of the disease to galvanize and guide now disparate research efforts, so that scientific discoveries are applied to common goals that advance both psoriasis and co-morbid conditions. Appropriations Bill: Labor, Health and Human Services, and Education Federal Agency: Department of Health and Human Services National Institutes of Health Account/Program: Office of the Director Project Justification Psoriasiswhich most often first strikes between age 15 and 25requires steadfast treatment and lifelong attention. Unfortunately, psoriasis often is overlooked or dismissed, because it is not typically a direct cause of death. It is commonly and incorrectly considered by insurers, employers, policymakers and the public as a mere annoyancea superficial problem, mistakenly thought to be contagious and/or due to poor hygiene. Psoriasis is in fact an often disabling autoimmune disease, with a genetic basis that starts below the skin surface and can cause severe pain, disability and adverse mental health effects and is associated with a variety of other serious health conditions. Up to 30 percent of people with psoriasis also develop psoriatic arthritis, which causes pain, stiffness and swelling in and around the joints. Without treatment, psoriatic arthritis can be potentially disabling and crippling. Individuals with psoriasis are at elevated risk for other chronic and serious health conditions, such as heart attack, diabetes, Crohns disease, obesity and liver disease and are twice as likely to have thoughts of suicide as people without psoriasis or with other chronic conditions. Studies have shown that psoriasis causes as much disability as other major chronic diseases. Other recent studies have established that people with severe psoriasis die four years younger, on average, than those who do not have psoriasis. The prevalence of depression in patients with moderate to severe psoriasis is approximately 24 percent, as compared to an estimated 6.7 percent of the adult U.S. population.
H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.
Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
Support for the continuation of psoriasis and psoriatic arthritis data collection efforts at the Centers for Disease Control and Prevention (CDC). Allocate $1.2 million in the Fiscal Year 2013 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at CDC. With this funding, the CDCs National Center for Chronic Disease Prevention and Health Promotion could begin implementation of its public health agenda that, if implemented, will: 1. Increase the understanding of psoriasis, including the prevalence of the diseases and how age, sex, race and ethnicity affect the course and burden of psoriasis; 2. Study how differences in genetic and non-genetic factors, such as environmental exposure and life-style, contribute to the occurrence and severity of psoriasis and psoriatic arthritis; 3. Examine the relationship of psoriasis to other serious diseases and develop public health strategies to reduce the burden of diseases and prevent the onset of comorbid conditions; and 4. Gain insight into the long-term impact of psoriasis and psoriatic arthritis.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
Support for the continuation of psoriasis and psoriatic arthritis data collection efforts at the Centers for Disease Control and Prevention (CDC). Allocate $1.2 million in the Fiscal Year 2013 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at CDC. With this funding, the CDCs National Center for Chronic Disease Prevention and Health Promotion could begin implementation of its public health agenda that, if implemented, will: 1. Increase the understanding of psoriasis, including the prevalence of the diseases and how age, sex, race and ethnicity affect the course and burden of psoriasis; 2. Study how differences in genetic and non-genetic factors, such as environmental exposure and life-style, contribute to the occurrence and severity of psoriasis and psoriatic arthritis; 3. Examine the relationship of psoriasis to other serious diseases and develop public health strategies to reduce the burden of diseases and prevent the onset of comorbid conditions; and 4. Gain insight into the long-term impact of psoriasis and psoriatic arthritis.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.
Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
Support for the continuation of psoriasis and psoriatic arthritis data collection efforts at the Centers for Disease Control and Prevention (CDC). SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017.
Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SECTION 4. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION Authorizes the Centers for Disease Control and Prevention (CDC) to undertake psoriasis and psoriatic arthritis data collection efforts including: incorporating questions into existing public health surveys, questionnaires and other databases to collect information regarding prevalence in the United States, age of onset, health-related quality of life, health care utilization, burden of disease (employment, work, etc.), direct and indirect costs, health disparities (age, gender, racial, ethnic), comorbidities and natural history of disease. These efforts may include the consideration and development of a patient registry, which would include individuals of all ages. SECTION 5. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS Non-binding language that: Recognizes that the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases. Commends the non-profit and private sector psoriasis research communities for planning a multi-disciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions. Encourages the National Institutes of Health (NIH) to continue to work with the organizations and private sector stakeholders who convene the multi-disciplinary scientific meeting to discuss future directions of psoriasis and comorbid research. Suggests that the non-profit and private sector meeting conveners disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from NIH and other relevant federal agencies. Encourages the Secretary of the Department of Health and Human Services (HHS), acting through the Director of the NIH, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) and other NIH institutes and centers, to utilize the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research and to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged
Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE